Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 721 to 730 of 2440 total matches.
Drugs for Psychotic Disorders
The Medical Letter on Drugs and Therapeutics • Dec 19, 2016 (Issue 1510)
in Table 1 on page 161. Parenteral
antipsychotic drugs used for treatment of these
disorders are listed ...
Oral antipsychotic drugs used for treatment of
schizophrenia, schizoaffective disorder, delusional
disorder, and other manifestations of psychosis or
mania are listed in Table 1. Parenteral
antipsychotic drugs used for treatment of these
disorders are listed in Table 2.
Celecoxib Safety Revisited
The Medical Letter on Drugs and Therapeutics • Dec 19, 2016 (Issue 1510)
Celecoxib Safety Revisited
The results of a clinical trial (PRECISION)1 comparing ...
The results of a clinical trial (PRECISION) comparing
the cardiovascular safety of the COX-2 selective
NSAID celecoxib (Celebrex, and generics) with that
of ibuprofen and naproxen, which are nonselective,
have been described in the lay press in terms that may
overestimate the safety of celecoxib.
In Brief: PPIs and Torsades de Pointes
The Medical Letter on Drugs and Therapeutics • Dec 05, 2016 (Issue 1509)
.1
PPIs do not directly cause prolongation of the QT interval, but they have been associated ...
Therapeutics (AZCERT) has recently added the proton pump inhibitors (PPIs) omeprazole (Prilosec, and others), esomeprazole (Nexium, and others), lansoprazole (Prevacid, and others), and pantoprazole (Protonix, and generics) to its lists of Drugs with Conditional Risk of Torsades de Pointes (TdP) and Drugs to Avoid in Patients with Congenital Long QT Syndrome.1PPIs do not directly cause prolongation of the QT interval, but they can cause hypomagnesemia, which is often accompanied by hypocalcemia and hypokalemia and can result in cardiac repolarization disturbances such as QT interval...
In Brief: Phentermine (Lomaira) for Weight Loss
The Medical Letter on Drugs and Therapeutics • Dec 05, 2016 (Issue 1509)
with
topiramate for years.1
Table 1. Phentermine Products
Usual
Drug Formulations Dosage Cost1
Phentermine2 ...
The FDA has approved Lomaira (KVK Tech), an 8-mg tablet formulation of phentermine that can be taken up to three times daily before meals, as an adjunct to lifestyle modifications for weight loss. It is only approved for short-term use (a few weeks) in adults with a body mass index (BMI) ≥30 kg/m2, or with a BMI ≥27 kg/m2 in addition to a weight-related comorbidity such as hypertension, dyslipidemia, or diabetes. Phentermine has been available alone and in combination with topiramate for years.1Lomaira was approved by the FDA under an abbreviated new drug application (ANDA) and is...
Sublingual Nitroglycerin Powder (GoNitro)
The Medical Letter on Drugs and Therapeutics • Dec 05, 2016 (Issue 1509)
of
nitroglycerin (NitroMist, Nitrolingual Pumpspray, and
generics) are also available.1
CLINICAL STUDIES ...
The FDA has approved a sublingual powder formulation
of nitroglycerin (GoNitro – Espero) for prevention
or acute relief of an attack of angina pectoris. It
is the first powder formulation of nitroglycerin to
become available in the US. Most patients with
angina use sublingual nitroglycerin tablets (Nitrostat,
and generics). Translingual spray formulations of
nitroglycerin (NitroMist, Nitrolingual Pumpspray, and
generics) are also available.
Ciprofloxacin/Fluocinolone (Otovel) for Otitis Media with Tympanostomy Tubes
The Medical Letter on Drugs and Therapeutics • Dec 05, 2016 (Issue 1509)
0.1% (Ciprodex) has been available
for many years. In December 2015, a suspension
of ciprofloxacin 6 ...
The FDA has approved Otovel (Arbor), a combination
of the fluoroquinolone antibiotic ciprofloxacin 0.3% and
the corticosteroid fluocinolone acetonide 0.025%, for
otic treatment of acute otitis media with tympanostomy
tubes (AOMT) in children ≥6 months old. It is the
second fluoroquinolone/corticosteroid combination
to be approved for this indication; ciprofloxacin 0.3%/dexamethasone 0.1% (Ciprodex) has been available
for many years. In December 2015, a suspension
of ciprofloxacin 6% (Otiprio) was approved for otic
treatment of bilateral otitis media with effusion in
children...
Ameluz for Actinic Keratoses
The Medical Letter on Drugs and Therapeutics • Dec 05, 2016 (Issue 1509)
2002.1
Pronunciation Key
Aminolevulinic acid: a mee" noe lev" ue lin' ik as' id
Ameluz: am' e looz ...
The FDA has approved a 10% nanoemulsion gel
formulation of the porphyrin-based photosensitizer
aminolevulinic acid hydrochloride (ALA; Ameluz –
Biofrontera) for use in combination with a narrowband
red light photodynamic therapy (PDT) lamp (BF-RhodoLED)
for treatment of actinic keratoses (AKs)
of mild to moderate severity on the face and scalp.
A 20% ALA solution (Levulan Kerastick) approved for
use in combination with blue light PDT (BLU-U) has
been available in the US since 2002.
Addendum: Statins for Primary Prevention of Cardiovascular Disease
The Medical Letter on Drugs and Therapeutics • Dec 05, 2016 (Issue 1509)
:133)
In our recent article on Lipid-Lowering Drugs,1 we said
that statins can reduce the risk ...
In our recent article on Lipid-Lowering Drugs,1 we said that statins can reduce the risk of first cardiovascular events and death (primary prevention) in patients at high risk for atherosclerotic cardiovascular disease (CVD) and significantly reduce the incidence of cardiovascular events in patients at lower risk for CVD. Now the United States Preventive Services Task Force (USPSTF) has issued new recommendations on the appropriate use of statins for primary prevention of CVD.2The USPSTF states that clinicians should periodically screen all persons 40-75 years old for cardiovascular risk...
Drugs for Head Lice
The Medical Letter on Drugs and Therapeutics • Nov 21, 2016 (Issue 1508)
, but especially
in elementary school children. In most cases,
transmission occurs by head-to-head contact.1 ...
Head lice infestation occurs in all age groups, but especially
in elementary school children. In most cases,
transmission occurs by head-to-head contact.
Minimed 670G: A Hybrid Closed-Loop Insulin Delivery System
The Medical Letter on Drugs and Therapeutics • Nov 21, 2016 (Issue 1508)
≥14 years old with type 1 diabetes. The system
uses an algorithm to automatically adjust basal ...
The FDA has approved the Minimed 670G (Medtronic),
a hybrid closed-loop insulin delivery system for use in
patients ≥14 years old with type 1 diabetes. The system
uses an algorithm to automatically adjust basal insulin
doses based on readings from a continuous glucose
monitor (CGM). It fully automates basal insulin
delivery in "auto" mode, but is considered a "hybrid"
system (not a true "artificial pancreas") because it
requires some action by the patient. The 670G system
is expected to become available in Spring 2017.